Healthcare and cell therapy in Bulgaria: verify authority, product and site
EU membership and a Bulgarian healthcare licence do not automatically authorise a cell product, clinical trial, hospital exemption or therapeutic claim.
Separate the layers of oversight. A healthcare facility licence concerns the establishment and activities in its scope. Tissue-and-cell rules can cover donation, testing, processing and traceability. A medicinal-product authorisation, authorised clinical trial or national hospital exemption answers a different question about a specific product and use.
For a clinical trial, request the sponsor, protocol, EU Clinical Trials Information System identifier, Bulgarian Drug Agency decision, ethics review, sites and recruitment status. Facility experience or a general statement that it can conduct trials does not authorise a new protocol, product or participant cohort.
For treatment outside a trial, request the exact product, indication and legal reference. A hospital exemption is not a general route for routine commercial access; the EU framework requires restrictive patient-, hospital- and Member-State conditions supervised by the national authority. Verify the reference directly rather than relying on a provider summary.
Check manufacturing documents at product and site level: holder, address, authorised activities, product relevance, inspections, scope and validity. Lower operating costs, investment or EU location do not prove equivalent manufacturing, clinical skill or outcomes. Compare current written quotations only after product and service scope match.
The Bulgarian Drug Agency trial-approval service, European Commission ATMP overview and EMA/HMA warning are starting points. A legal and regulatory professional should verify any clinic-specific conclusion.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.